BRCA1 and ovarian cancer: In breast and ovarian cancer, the first case–control study predicting BC [141] in women without any pathogenic variants in BRCA1/2 genes developed an SNP18 PRS with an OR of 1.55 (95% CI 1.29 to 1.87) and an AUC of 0.59, demonstrating the PRS feasibility.